DBV Technologies Expands Viaskin Peanut Program to Infants with Peanut Allergies

A Phase 2 Study in Infants with Peanut Allergies

DBV Technologies has announced the screening of the first participant in the THRIVE study, a phase 2 clinical trial dedicated to the Viaskin Peanut Patch. This study evaluates the efficacy and safety of the patch with the goal of achieving ad lib consumption of peanut food in infants aged 6 to 12 months who have a peanut allergy. The first participant was selected by Dr. Douglas Mack, assistant clinical professor in the department of pediatrics at McMaster University in Ontario.

A Daily Treatment Planned for a Duration of 36 Months

According to the press release, THRIVE is an open, single-arm phase 2 study. All participants will receive the Viaskin Peanut patch daily for 36 months, while maintaining a peanut-free diet. At the end of this period, a peanut food challenge will be conducted to determine the consumption regimen applicable for the following twelve months, between months 37 and 48 of the study. Depending on the results of this test, some participants may enter this consumption period without continuing the patch treatment, while others will continue to wear the device.

A Clinical Program Expanded to a Younger Population

DBV Technologies presents this study as an extension of its clinical program to a younger patient population. Daniel Tassé, the company's CEO, states that the launch of the screening in THRIVE marks a step in DBV's mission to transform the management of children and families dealing with peanut allergies. The executive also highlights that this study follows positive clinical results observed in toddlers aged 1 to 3 years and in children aged 4 to 7 years.